PERSONALIZED MEDICINE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

Accompanying the explosion in biomedical knowledge is the evolution of laboratory tools, informatics, and therapeutics that are fueling the advancement of personalized medicine. A plethora of innovative molecular diagnostic tests have entered the market in the past few years, from DNA microarrays capable of analyzing hundreds of thousands of genetic markers in a single test to next-generation sequencing platforms capable of decoding a person's entire genome at unprecedented speed and affordability. Meanwhile, technologies like liquid biopsies offer less invasive means of detecting cancer by analyzing fragments of tumor DNA in blood samples. These diagnostic capabilities are powering the discovery of novel biomarkers with potential clinical utility. Therapeutically, the fields of genomic medicine, pharmacogenomics, and precision therapeutics are also progressing rapidly owing to advancements in areas like targeted drug design, cell and gene therapy, and immunotherapy. Promising new personalized treatment approaches are demonstrating success against various cancers, offering hope that precision medicine may one day revolutionize how to prevent and cure many intractable illnesses. Although regulatory and clinical adoption challenges remain, the evolving toolbox of diagnostic platforms and targeted drugs will continue enabling and accelerating the translation of research insights into practical benefits for patients.

• Precision Biologics
• Danaher Corporation
• Abbott
• Illumina, Inc.
• Exact Sciences Corporation
• ASURAGEN, INC.
• Exagen Inc.
• Genentech, Inc.
• Berg Health
• Omada Health
• Natera
• Invitae
• Myriad Genetics
• Celcuity
• InsightRX 
• Axial3D